Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.NS)
INR 689.05
(0.15%)
INR 689.05
(0.15%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 424.96 Million | 466.54 Million | 55.98 Million | 282.22 Million | 112.47 Million | 308.98 Million |
| Net Income | 224.63 Million | 348.08 Million | 273.19 Million | 218.72 Million | 94.14 Million | 90.02 Million |
| Depreciation & Amortization | 16.62 Million | 12.05 Million | 15.26 Million | 10.86 Million | 11.29 Million | 10.15 Million |
| Deferred income taxes | 7.07 Million | -77.62 Million | - | - | - | - |
| Stock-based compensation | 133.1 Million | 87.65 Million | - | - | - | - |
| Change in working capital | 55.39 Million | 98.74 Million | -171.29 Million | 115.94 Million | 42.54 Million | 197.1 Million |
| Other non-cash items | 99.68 Million | -2.36 Million | -61.17 Million | -63.3 Million | -35.51 Million | 11.69 Million |
| Investing Cash Flow | -319.15 Million | -576.7 Million | -262.07 Million | -22.64 Million | -107.62 Million | -8.25 Million |
| Investments in PPE | -2.48 Million | -3.17 Million | -4.67 Million | -4.69 Million | -20.68 Million | -22.54 Million |
| Acquisitions | - | 12.96 Million | 5.81 Million | - | - | 22.54 Million |
| Investment purchases | -1.35 Billion | -1.03 Billion | -284.48 Million | -41.72 Million | -113.86 Million | - |
| Sales/Maturities of investments | 1.03 Billion | 412.19 Million | -5.81 Million | - | - | - |
| Other Investing Activities | -243 Million | 34.27 Million | 27.08 Million | 23.77 Million | 26.91 Million | -8.25 Million |
| Financing Cash Flow | -88.74 Million | -4.56 Million | -123.03 Million | -68.28 Million | -9.44 Million | -60.5 Million |
| Debt repayment | -6.33 Million | -3.22 Million | -67.88 Million | - | -8.79 Million | -22 Million |
| Dividends payments | -130.99 Million | - | -104.79 Million | -26.2 Million | -13.1 Million | -6.55 Million |
| Common Stock Repurchased | - | - | - | -36.94 Million | - | - |
| Common Stock Issuance | 56.35 Million | - | - | - | - | - |
| Other Financing Activities | 48.21 Million | -1.34 Million | 49.63 Million | -5.13 Million | 3.65 Million | -31.94 Million |
| Accounts receivables | 91.54 Million | -55.56 Million | -29.55 Million | 87.89 Million | -7.03 Million | 44.03 Million |
| Accounts payables | -89.82 Million | -19.62 Million | -10.75 Million | 63.4 Million | -1.51 Million | 27.67 Million |
| Inventory | 53.1 Million | 90.65 Million | -176 Thousand | -3.99 Million | 33.67 Million | 187.41 Million |
| Other working capital | 570 Thousand | 83.26 Million | -130.81 Million | -31.36 Million | 17.4 Million | -62.02 Million |
| Cash at beginning of period | 110.53 Million | 225.26 Million | 589.42 Million | 398.13 Million | 385.34 Million | 145.12 Million |
| Cash at end of period | 1.47 Billion | 110.53 Million | 260.29 Million | 589.42 Million | 380.74 Million | 385.34 Million |
| Capital Expenditure | -2.48 Million | -3.17 Million | -4.67 Million | -4.69 Million | -20.68 Million | -22.54 Million |
| Effect of forex changes on cash | - | 3000.00 | -35.03 Million | - | 17.38 Million | - |
| Net cash flow / Change in cash | 1.36 Billion | -114.73 Million | -329.13 Million | 191.29 Million | -4.6 Million | 240.22 Million |
| Free Cash Flow | 422.48 Million | 463.36 Million | 51.3 Million | 277.53 Million | 91.79 Million | 286.43 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 53.29 Million | 224.63 Million | 35.49 Million | 39.63 Million | 74.72 Million | 74.79 Million |
| Depreciation & Amortization | - | 16.62 Million | - | 4.12 Million | 4.55 Million | 3.93 Million |
| Deferred income taxes | - | 7.07 Million | - | - | - | - |
| Stock-based compensation | 24.25 Million | 133.1 Million | 22.74 Million | 26.52 Million | 41.81 Million | 42.03 Million |
| Change in working capital | - | 55.39 Million | - | - | - | - |
| Other non-cash items | -77.54 Million | 99.68 Million | -58.23 Million | -66.15 Million | -116.53 Million | -116.82 Million |
| Investing Cash Flow | - | -319.15 Million | - | - | - | - |
| Investments in PPE | - | -2.48 Million | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -1.35 Billion | - | - | - | - |
| Sales/Maturities of investments | - | 1.03 Billion | - | - | - | - |
| Other Investing Activities | - | -243 Million | - | - | - | - |
| Financing Cash Flow | - | -88.74 Million | - | - | - | - |
| Debt repayment | - | -6.33 Million | - | - | - | - |
| Dividends payments | - | -130.99 Million | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 56.35 Million | - | - | - | - |
| Other Financing Activities | - | 48.21 Million | - | - | - | - |
| Accounts receivables | - | 91.54 Million | - | - | - | - |
| Accounts payables | - | -89.82 Million | - | - | - | - |
| Inventory | - | 53.1 Million | - | - | - | - |
| Other working capital | - | 570 Thousand | - | - | - | - |
| Cash at beginning of period | - | 110.53 Million | - | 1.11 Billion | 1.06 Billion | 110.53 Million |
| Cash at end of period | - | 1.47 Billion | - | 1.12 Billion | 1.11 Billion | 42.03 Million |
| Capital Expenditure | - | -2.48 Million | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | 1.36 Billion | - | 8.24 Million | 50.91 Million | -68.5 Million |
| Free Cash Flow | - | 422.48 Million | - | 8.24 Million | 50.91 Million | 42.03 Million |
G1A
JROOF
600251
NXC
AKZOY
PUR